A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) is a major cause of cancer-related death. It is a highly vascular tumour with multiple angiogenic factors, most importantly vascular endothelial growth factor (VEGF), involved in HCC progression. Tivozanib is an oral inhibitor of VEGFR-1/2/3 with promising...

Descripción completa

Detalles Bibliográficos
Autores principales: Fountzilas, Christos, Gupta, Medhavi, Lee, Sunyoung, Krishnamurthi, Smitha, Estfan, Bassam, Wang, Katy, Attwood, Kristopher, Wilton, John, Bies, Robert, Bshara, Wiam, Iyer, Renuka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109127/
https://www.ncbi.nlm.nih.gov/pubmed/32037403
http://dx.doi.org/10.1038/s41416-020-0737-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109127/
https://www.ncbi.nlm.nih.gov/pubmed/32037403
http://dx.doi.org/10.1038/s41416-020-0737-6

Ejemplares similares